Dr. Géraldine Androdias reveals how immune checkpoint inhibitors affect multiple sclerosis, highlighting a low risk of relapse in MS patients undergoing cancer treatments. Dr. Bob Fox dives into the significance of neurofilament light chain as a biomarker for disease progression, stressing the need for more research. Dr. Ellen Iacobaeus discusses the unique clinical traits of late-onset MS, advocating for personalized therapy approaches. Additionally, insights on family planning for MS patients underscore the importance of supportive discussions between patients and healthcare providers.